{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"1.950","floor":"1.500"},"ipodate":{"start":"2019-05-20 00:00:00","end":"2019-05-24 00:00:00"},"minimumcapital":"3939.31","subscribed":"1.46","marketcap":"61.86億","H_marketcap":"--","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/02181/LTN20190520006_C.pdf","ipopricing":"1.500","resultdate":"2019-05-30 00:00:00","enddate":"2019-05-24 00:00:00","listeddate":"2019-05-31 00:00:00","issuenumber":"78358.00萬","issuenumberhK":"7835.80萬","issuenumberother":"70522.20萬","grayprice":"1.45","sponsors":"中國國際金融香港證券有限公司","raisemoney":"106810.00萬","use":"1、約70.1%或748.7百萬港元將用于我們的核心候選產品CMAB007、CMAB008及CMAB009；\n2、約20.1%或214.7百萬港元將用于我們其他候選產品的研發活動；\n3、約9.8%或104.7百萬港元將用作營運資金及其他一般企業用途。","shares":2000,"leadagent":"","bookrunners":"中國國際金融香港證券有限公司","coordinator":"中國國際金融香港證券有限公司","firstDayOpen":"1.50","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"中國國際金融香港證券有限公司","code":"E02181","name":"邁博藥業—Ｂ","fullname":"邁博藥業有限公司"},"institutioninfo":{"principaloffice":"中國泰州中國醫藥城口泰路西側陸家路東側G79幢","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"焦樹閣","secretary":"李云峰,曾浩賢","telephone":"(852) 3150 6788","substantialshareholders":"Asia Mabtech(49.95%),CDH PE(18%),FH Investment(5.18%)","principalactivities":"公司是中國領先的生物醫藥公司，專注于癌癥和自身免疫性疾病新藥及生物類似藥的研發和生產。","website":"http://www.mabpharm.cn"},"managerinfo":[{"managername":"焦樹閣","post":"主席兼非執行董事","rankno":1},{"managername":"錢衛珠","post":"行政總裁兼執行董事","rankno":2},{"managername":"王皓","post":"首席科學家兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"三生制藥","shareholding":"130,818,000.0","percentage":16.69,"ReleaseDate":"2019-11-30 00:00:00","relatedparty":"CITIC PE Funds Limited","subsidiary":["三生制藥"],"InverstorType":"公司"}],"TotalShareholdingPercentage":16.69},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":519}